Terms: = Bone cancer AND IRF4, LSIRF, 3662, ENSG00000137265, Q15306
60 results:
1. Interferon regulatory factor 4 plays a pivotal role in the development of aGVHD-associated colitis.
Frueh JT; Campe J; Sunaga-Franze DY; Verheyden NA; Ghimire S; Meedt E; Haslinger D; Harenkamp S; Staudenraus D; Sauer S; Kreft A; Schubert R; Lohoff M; Krueger A; Bonig H; Chiocchetti AG; Zeiser R; Holler E; Ullrich E
Oncoimmunology; 2024; 13(1):2296712. PubMed ID: 38170159
[TBL] [Abstract] [Full Text] [Related]
2. Phenotype-structured model of intra-clonal heterogeneity and drug resistance in multiple myeloma.
Bouchnita A; Volpert V
J Theor Biol; 2024 Jan; 576():111652. PubMed ID: 37952610
[TBL] [Abstract] [Full Text] [Related]
3. Longitudinal treatment outcomes of recurrent clival chordomas: a single-center retrospective study.
Hong S; Mahajan A; Shinya Y; Laack NN; Link MJ; O'Brien EK; Stokken JK; Janus JR; Ho TP; Choby G; Van Gompel JJ
J Neurosurg; 2024 Apr; 140(4):920-928. PubMed ID: 37856417
[TBL] [Abstract] [Full Text] [Related]
4. Emerging entities: high-grade/large B-cell lymphoma with 11q aberration, large B-cell lymphoma with irf4 rearrangement, and new molecular subgroups in large B-cell lymphomas. A report of the 2022 EA4HP/SH lymphoma workshop.
Quintanilla-Martinez L; Laurent C; Soma L; Ng SB; Climent F; Ondrejka SL; Zamo A; Wotherspoon A; de Leval L; Dirnhofer S; Leoncini L
Virchows Arch; 2023 Sep; 483(3):281-298. PubMed ID: 37555980
[TBL] [Abstract] [Full Text] [Related]
5. Heterogeneity of B cell lymphopoiesis in patients with premalignant and active myeloma.
Jakubikova J; Cholujova D; Beke G; Hideshima T; Klucar L; Leiba M; Jamroziak K; Richardson PG; Kastritis E; Dorfman DM; Anderson KC
JCI Insight; 2023 Feb; 8(3):. PubMed ID: 36752202
[TBL] [Abstract] [Full Text] [Related]
6. irf4 deficiency vulnerates B-cell progeny for leukemogenesis via somatically acquired Jak3 mutations conferring IL-7 hypersensitivity.
Das Gupta D; Paul C; Samel N; Bieringer M; Staudenraus D; Marini F; Raifer H; Menke L; Hansal L; Camara B; Roth E; Daum P; Wanzel M; Mernberger M; Nist A; Bauer UM; Helmprobst F; Buchholz M; Roth K; Bastian L; Hartmann AM; Baldus C; Ikuta K; Neubauer A; Burchert A; Jäck HM; Klein M; Bopp T; Stiewe T; Pagenstecher A; Lohoff M
Cell Death Differ; 2022 Nov; 29(11):2163-2176. PubMed ID: 35459909
[TBL] [Abstract] [Full Text] [Related]
7. Plasma cell dependence on histone/protein deacetylase 11 reveals a therapeutic target in multiple myeloma.
Mostofa A; Distler A; Meads MB; Sahakian E; Powers JJ; Achille A; Noyes D; Wright G; Fang B; Izumi V; Koomen J; Rampakrishnan R; Nguyen TP; De Avila G; Silva AS; Sudalagunta P; Canevarolo RR; Siqueira Silva MDC; Alugubelli RR; Dai HA; Kulkarni A; Dalton WS; Hampton OA; Welsh EA; Teer JK; Tungesvik A; Wright KL; Pinilla-Ibarz J; Sotomayor EM; Shain KH; Brayer J
JCI Insight; 2021 Dec; 6(24):. PubMed ID: 34793338
[TBL] [Abstract] [Full Text] [Related]
8. Oleil Hydroxytyrosol (HTOL) Exerts Anti-Myeloma Activity by Antagonizing Key Survival Pathways in Malignant Plasma Cells.
Todoerti K; Gallo Cantafio ME; Oliverio M; Juli G; Rocca C; Citraro R; Tassone P; Procopio A; De Sarro G; Neri A; Viglietto G; Amodio N
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769070
[TBL] [Abstract] [Full Text] [Related]
9. Immunomodulatory effect of NEDD8-activating enzyme inhibition in Multiple Myeloma: upregulation of NKG2D ligands and sensitization to Natural Killer cell recognition.
Petillo S; Capuano C; Molfetta R; Fionda C; Mekhloufi A; Pighi C; Antonangeli F; Zingoni A; Soriani A; Petrucci MT; Galandrini R; Paolini R; Santoni A; Cippitelli M
Cell Death Dis; 2021 Sep; 12(9):836. PubMed ID: 34482362
[TBL] [Abstract] [Full Text] [Related]
10. Feasibility and effectiveness of afatinib for poor performance status patients with EGFR-mutation-positive non-small-cell lung cancer: a retrospective cohort study.
Wu CE; Chang CF; Huang CY; Yang CT; Kuo CS; Hsu PC; Chang JW
BMC Cancer; 2021 Jul; 21(1):859. PubMed ID: 34315431
[TBL] [Abstract] [Full Text] [Related]
11. Impact of hypoxia on the pathogenesis and therapy resistance in multiple myeloma.
Ikeda S; Tagawa H
Cancer Sci; 2021 Oct; 112(10):3995-4004. PubMed ID: 34310776
[TBL] [Abstract] [Full Text] [Related]
12. Sensitive intranuclear flow cytometric quantification of irf4 protein in multiple myeloma and normal human hematopoietic cells.
Vora AA; Mondala PK; Costello C; MacLeod AR; Crews LA
STAR Protoc; 2021 Jun; 2(2):100565. PubMed ID: 34136833
[TBL] [Abstract] [Full Text] [Related]
13. Lenalidomide abrogates the survival effect of bone marrow stromal cells in chronic lymphocytic leukemia.
Kriston C; Hernádfői M; Plander M; Márk Á; Takács F; Czeti Á; Szalóki G; Szabó O; Matolcsy A; Barna G
Hematol Oncol; 2021 Oct; 39(4):513-520. PubMed ID: 34013974
[TBL] [Abstract] [Full Text] [Related]
14. The IKZF1-irf4/IRF5 Axis Controls Polarization of Myeloma-Associated Macrophages.
Mougiakakos D; Bach C; Böttcher M; Beier F; Röhner L; Stoll A; Rehli M; Gebhard C; Lischer C; Eberhardt M; Vera J; Büttner-Herold M; Bitterer K; Balzer H; Leffler M; Jitschin S; Hundemer M; Awwad MHS; Busch M; Stenger S; Völkl S; Schütz C; Krönke J; Mackensen A; Bruns H
Cancer Immunol Res; 2021 Mar; 9(3):265-278. PubMed ID: 33563611
[TBL] [Abstract] [Full Text] [Related]
15. Selective antisense oligonucleotide inhibition of human irf4 prevents malignant myeloma regeneration via cell cycle disruption.
Mondala PK; Vora AA; Zhou T; Lazzari E; Ladel L; Luo X; Kim Y; Costello C; MacLeod AR; Jamieson CHM; Crews LA
Cell Stem Cell; 2021 Apr; 28(4):623-636.e9. PubMed ID: 33476575
[TBL] [Abstract] [Full Text] [Related]
16. Tissue methylation and demethylation influence translesion synthesis DNA polymerases (TLS) contributing to the genesis of chromosomal abnormalities in myelodysplastic syndrome.
Cavalcante GM; Borges DP; de Oliveira RTG; Furtado CLM; Alves APNN; Sousa AM; de Paula DS; Filho FDR; Magalhães SMM; Ribeiro-Jr HL; Pinheiro RF
J Clin Pathol; 2022 Feb; 75(2):85-93. PubMed ID: 33234697
[TBL] [Abstract] [Full Text] [Related]
17. Antimyeloma Potential of Caffeic Acid Phenethyl Ester and Its Analogues through Sp1 Mediated Downregulation of IKZF1-irf4-MYC Axis.
Murugesan A; Lassalle-Claux G; Hogan L; Vaillancourt E; Selka A; Luiker K; Kim MJ; Touaibia M; Reiman T
J Nat Prod; 2020 Dec; 83(12):3526-3535. PubMed ID: 33210536
[TBL] [Abstract] [Full Text] [Related]
18. Common gene variants within 3'-untranslated regions as modulators of multiple myeloma risk and survival.
Melaiu O; Macauda A; Sainz J; Calvetti D; Facioni MS; Maccari G; Ter Horst R; Netea MG; Li Y; Grząśko N; Moreno V; Jurczyszyn A; Jerez A; Watek M; Varkonyi J; Garcia-Sanz R; Kruszewski M; Dudziński M; Kadar K; Jacobsen SEH; Mazur G; Andersen V; Rybicka M; Zawirska D; Raźny M; Zaucha JM; Ostrovsky O; Iskierka-Jazdzewska E; Reis RM; Stępień A; Beider K; Nagler A; Druzd-Sitek A; Marques H; Martìnez-Lopez J; Lesueur F; Avet-Loiseau H; Vangsted AJ; Krawczyk-Kulis M; Butrym A; Jamroziak K; Dumontet C; Vogel U; Rymko M; Pelosini M; Subocz E; Szombath G; Sarasquete ME; Silvestri R; Morani F; Landi S; Campa D; Canzian F; Gemignani F
Int J Cancer; 2021 Apr; 148(8):1887-1894. PubMed ID: 33152124
[TBL] [Abstract] [Full Text] [Related]
19. Exploiting Protein Translation Dependence in Multiple Myeloma with Omacetaxine-Based Therapy.
Walker ZJ; Idler BM; Davis LN; Stevens BM; VanWyngarden MJ; Ohlstrom D; Bearrows SC; Hammes A; Smith CA; Jordan CT; Mark TM; Forsberg PA; Sherbenou DW
Clin Cancer Res; 2021 Feb; 27(3):819-830. PubMed ID: 33109736
[TBL] [Abstract] [Full Text] [Related]
20. HIV-associated plasmablastic lymphoma in the era of HAART: a single-center experience of 21 patients.
Mai B; Wang W; Lin M; Hu S; Wang XI; Chen L; Wahed A; Nguyen A; Ma HY; Medeiros LJ; Hu Z
AIDS; 2020 Oct; 34(12):1735-1743. PubMed ID: 32889849
[TBL] [Abstract] [Full Text] [Related]
[Next]
